- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.09. | ESC 2025: Novo Nordisk's Wegovy superior to Zepbound in reducing CV events | ||
| 01.09. | Eisai's Leqembi unlocks at-home dosing with FDA autoinjector approval | ||
| 01.09. | Santhera and Ikris sign distribution agreement for DMD drug in India | ||
| 01.09. | FDA approves Sanofi's BTK inhibitor for immune thrombocytopenia | ||
| 01.09. | VPAG stalemate threatens to exclude innovative medicines from the UK | ||
| 29.08. | Teva brings first generic GLP-1 to US market with Saxenda copycat approval | ||
| 29.08. | Chickenpox jab to be included on England's childhood vaccination programme | ||
| 29.08. | Outlook's wet AMD candidate hit with second FDA snub in two years | ||
| 29.08. | Health Canada issues NOC to AbbVie's upadacitinib for giant cell arteritis | ||
| 29.08. | MHRA approves GSK's oral antibiotic for UTIs in females | ||
| 28.08. | Podcast: Migration of clinical studies | ||
| 28.08. | Four drugs race for first bispecific ADC approval | ||
| 28.08. | Novo Nordisk enlists srRNA developer Replicate in $550m deal | ||
| 28.08. | Cell and gene therapies on correction course but not sinking | ||
| 28.08. | FDA approves mRNA vaccines for new Covid-19 season amid political tension | ||
| 28.08. | AI psychosis sees users 'co-creating delusions with technology' - expert | ||
| 28.08. | PCI Pharma Services completes acquisition of Ajinomoto Althea | ||
| 28.08. | FDA grants RMAT designation to Hope Biosciences' MS treatment | ||
| 28.08. | ExCellThera gains EC authorisation for Zemcelpro cell therapy | ||
| 27.08. | 2024 saw growth recovery for almost all top biopharma companies | ||
| 27.08. | Eli Lilly eyes orforglipron approval after Phase III diabetes trial success | ||
| 26.08. | FDA bans Ixchiq in the US, sending Valneva shares plummeting | ||
| 26.08. | Gilead's Yeytuo approved in EU, boosting its blockbuster potential | ||
| 26.08. | AbbVie agrees to acquire Gilgamesh's bretisilocin for $1.2bn | ||
| 26.08. | Genentech begins construction of North Carolina manufacturing site |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .